BioVision Lilly Award to honour scientists from developing countries

Prize will reward research into infectious diseases

BioVision and TWAS, the academy of sciences for the developing world, will honour outstanding scientific achievements made by individual young scientists from developing countries in the BioVision Lilly Award.

The prize will reward three young scientists living and working in a developing country, who have a track record of excellent research in infectious diseases, preferably with an emphasis on tuberculosis, and promise to have a positive impact in the developing world.

Candidates should be under 40 and hold at least a PhD.

Three winners will be selected and invited to attend BioVision 2011 in Lyon, France from 27-29 March.

The winner will receive US$5,000 and the runner-up $2,000, to be used for his or her research. The third prizewinner will receive an invitation to attend BioVision 2011, with travel and hotel costs paid.

The awards will be presented at a ceremony hosted by BioVision, TWAS and Lilly, during the exhibition.

The closing date for nominations is 15 January 2011.

You may also like

Research & Development

Agilent introduces the Altura Line of Inert HPLC Columns for superior results in biotherapeutic testing

Helping biopharma labs reach new heights in analytical performance
Regulatory

Novartis secures FDA approval for Rhapsido, the first oral BTKi treatment for chronic spontaneous urticaria

Rhapsido (remibrutinib) offers a new targeted option for CSU patients, showing rapid symptom control and a favourable safety profile without lab monitoring, as Novartis expands its immunology portfolio
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Building resilient outsourcing strategies: safeguarding oncology research samples against disaster risk (part I)

With a focus on the evolving landscape of biorepositories, this article explores the critical importance of robust outsourcing strategies to protect oncology research samples from disaster risk. Lori A. Ball, Chief Executive Officer at Astoriom, reports
Research & Development

Veraxa and Secarna Pharmaceuticals partner to advance AOC therapies for immune diseases

The pair will develop next-generation antibody oligonucleotide conjugates (AOCs) with the aim of unlocking novel targeted therapies for the treatment of autoimmune and chronic immune diseases
Media

Guardtech support staff member’s epic trek for cancer charity close to the business’ heart

The Haverhill cleanroom construction specialists donated £500 to Sarcoma UK to support their IT & Systems Manager Elliott Sheppard’s 25km trek in honour of his daughter Isobel
Research & Development

New small molecule shows promise in stopping lung cancer growth

Researchers have identified AVJ16, a drug candidate that blocks the cancer-driving protein IGF2BP1, halting tumour growth in preclinical models whilst sparing healthy cells
Manufacturing

Quantoom Biosciences partners with Memorial Sloan Kettering Cancer Center to advance personalised mRNA cancer therapeutics

Quantoom Biosciences will use MSK's proprietary lipid nanoparticle technology, Ncapsulate QCX-002, in the development of personalised RNA-based cancer therapies, with plans to support upcoming Phase I clinical trials
Subscribe now